公开(公告)号：US12121573B2

公开(公告)日：2024-10-22

申请号：US16924184

申请日：2020-07-09

申请人： Tianxin Wang

发明人： Tianxin Wang

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61K45/06

CPC分类号： A61K39/001106 ,  A61K39/395 ,  A61K2039/54 ,  A61K2039/6018 ,  A61K2039/876 ,  A61K45/06

摘要： This disclosure provides cell surface anchoring conjugates, formulations comprising cell surface anchoring conjugates, STING agonist and methods of using the same for boosting immunity in a subject and treating tumor cell and cancer.

公开(公告)号：US11945851B2

公开(公告)日：2024-04-02

申请号：US16619500

申请日：2018-06-07

申请人： The Wistar Institute of Anatomy and Biology

发明人： David Weiner ,  Elizabeth Duperret

IPC分类号： C07K14/47 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00

CPC分类号： C07K14/4748 ,  A61K39/001186 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  A61K2039/53 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/572 ,  A61K2039/86 ,  A61K2039/876

摘要： Disclosed herein are compositions and methods for treating and/or preventing cancer in mammals, and in particular, vaccines that treat and provide protection against tumor growth.

公开(公告)号：US20190209652A1

公开(公告)日：2019-07-11

申请号：US16335913

申请日：2017-09-22

申请人： OncoSec Medical Incorporated ,  The Regents of the University of California

发明人： Robert H. Pierce ,  Adil Daud

IPC分类号： A61K38/20 ,  A61N1/32 ,  C07K16/28 ,  A61P35/00 ,  A61K9/00

CPC分类号： A61K38/20 ,  A61K9/0009 ,  A61K9/0019 ,  A61K38/208 ,  A61K39/39558 ,  A61K41/0047 ,  A61K2039/505 ,  A61K2039/55 ,  A61K2039/876 ,  A61N1/327 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/76 ,  A61K2300/00

摘要： The present invention provides for a dosing schedule for the intratumoral delivery of an immunostimulatory cytokine in combination with systemic delivery of a checkpoint inhibitor. In particular, it provides delivery of a plasmid encoding the immunostimulatory cytokine, e.g., IL-12, using intratumoral electroporation, and the systemic delivery of a PD-1 antagonist.

公开(公告)号：US20180235886A1

公开(公告)日：2018-08-23

申请号：US15752155

申请日：2016-08-18

申请人： Mayo Foundation for Medical Education and Research

发明人： Svetomir N. Markovic ,  Wendy K. Nevala

IPC分类号： A61K9/19 ,  A61K47/68 ,  C07K14/765 ,  C07K16/22 ,  C07K16/32

CPC分类号： A61K9/19 ,  A61K9/0019 ,  A61K9/14 ,  A61K31/337 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/643 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6929 ,  A61K2039/505 ,  A61K2039/876 ,  A61K2300/00 ,  A61P35/00 ,  C07K14/765 ,  C07K16/22 ,  C07K16/2887 ,  C07K16/32 ,  C07K2317/73 ,  C07K2317/94

摘要： Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic.

公开(公告)号：US20230414741A1

公开(公告)日：2023-12-28

申请号：US18248861

申请日：2021-10-12

申请人： HPVVAX, LLC

发明人： Tim Ioannides ,  Evangelos V. Badiavas

IPC分类号： A61K39/12 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00 ,  A61K31/197 ,  A61K31/7105 ,  C07K16/28

CPC分类号： A61K39/12 ,  A61P35/00 ,  A61K39/3955 ,  A61K39/4611 ,  A61K39/4622 ,  A61K39/4633 ,  A61K2039/53 ,  A61K31/7105 ,  C07K16/2818 ,  C07K16/2827 ,  A61K39/4631 ,  A61K2039/876 ,  A61K2239/57 ,  A61K31/197

摘要： A method for treating or reducing the incidence of recurrence of cancer, benign tumors, or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering to a patient one or more doses of HPV recombinant vaccine as a first active therapeutic agent in combination with a second active therapeutic agent administered concomitantly or as a fixed-dose combination composition.

公开(公告)号：US20230381291A1

公开(公告)日：2023-11-30

申请号：US18004831

申请日：2021-07-08

申请人： HUMANITAS MIRASOLE S.P.A. ,  HUMANITAS UNIVERSITY ,  ISTITUTO EUROPEO DI ONCOLOGIA S.R.L.

发明人： Maria RESCIGNO ,  Alessia MELACARNE ,  Giuseppe PENNA

IPC分类号： A61K39/00 ,  A61P37/04

CPC分类号： A61K39/0011 ,  A61P37/04 ,  A61K2039/5154 ,  A61K2039/876

摘要： The present invention provides antigen presenting cells (APC) carrying human tumor-associated peptides on the cell surface as well as immunogenic compositions including the tumor-associated peptides and/or the antigen presenting cells according to the invention. The immunogenic composition of the invention is useful as a vaccine in the prevention and/or treatment of a tumor disease, particularly melanoma and melanoma residual disease.

公开(公告)号：US20230338452A1

公开(公告)日：2023-10-26

申请号：US18336614

申请日：2023-06-16

申请人： Imam Abdulrahman Bin Faisal University

发明人： Sahar K. AL-DOSARY

IPC分类号： A61P31/04 ,  A61K39/09 ,  A61K39/108 ,  A61K36/324

CPC分类号： A61K36/324 ,  A61K39/0266 ,  A61K39/092 ,  A61P31/04 ,  A61K2039/876 ,  A61K2236/333

摘要： A method for treating a microbial infection, especially pneumonia, comprising administering an aqueous-ethanol extract of Thymus or Boswellia or a composition containing the extract. Aqueous-ethanol extracts of Thymus and/or Boswellia.

公开(公告)号：US20170253633A1

公开(公告)日：2017-09-07

申请号：US15445461

申请日：2017-02-28

申请人： IMMATICS BIOTECHNOLOGIES GMBH

发明人： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC分类号： C07K7/08 ,  C07K16/18 ,  G01N33/68 ,  A61K35/17 ,  A61K39/00 ,  C12N15/115 ,  C07K7/06 ,  C07K14/725

CPC分类号： C07K7/08 ,  A61K35/17 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/80 ,  A61K2039/804 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/828 ,  A61K2039/836 ,  A61K2039/844 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/876 ,  A61K2039/884 ,  A61K2039/892 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K2319/00 ,  C12N15/115 ,  C12N2310/16 ,  G01N33/6893 ,  G01N2800/52

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240335473A1

公开(公告)日：2024-10-10

申请号：US18745733

申请日：2024-06-17

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Greg M. Delgoffe

IPC分类号： A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/17 ,  A61K38/20 ,  A61K39/00 ,  A61K39/39 ,  A61K45/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/1774 ,  A61K38/2013 ,  A61K39/00119 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C12N5/0636 ,  A61K2039/5158 ,  A61K2039/876 ,  A61K45/05 ,  A61K2800/78 ,  C12N2501/39 ,  C12N2501/999

摘要： The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1α in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1α include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods.

公开(公告)号：US12048717B2

公开(公告)日：2024-07-30

申请号：US16303828

申请日：2017-06-05

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Greg M. Delgoffe

IPC分类号： A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/17 ,  A61K38/20 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783 ,  A61K45/00

CPC分类号： A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/1774 ,  A61K38/2013 ,  A61K39/00119 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C12N5/0636 ,  A61K2039/5158 ,  A61K2039/876 ,  A61K45/05 ,  A61K2800/78 ,  C12N2501/39 ,  C12N2501/999 ,  A61K38/2013 ,  A61K2300/00

摘要： The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1α in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1α include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods.